Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children's Oncology Group
Open Access
- 19 September 2006
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 109 (1), 46-51
- https://doi.org/10.1182/blood-2006-01-023101
Abstract
This study describes the magnitude of risk of therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) in 578 individuals diagnosed with Ewing sarcoma and enrolled on Children's Oncology Group therapeutic protocol, INT-0091. Between 1988 and 1992, patients with or without metastatic disease were randomized to receive doxorubicin, vincristine, cyclophosphamide, and dactinomycin (regimen A) or these 4 drugs alternating with etoposide and ifosfamide (regimen B). Between 1992 and 1994, patients with metastatic disease were nonrandomly assigned to receive high-intensity therapy (regimen C: regimen B therapy with higher doses of doxorubicin, cyclophosphamide, and ifosfamide). Median age at diagnosis of Ewing sarcoma was 12 years, and median length of follow-up, 8 years. Eleven patients developed t-MDS/AML, resulting in a cumulative incidence of 2% at 5 years. While patients treated on regimens A and B were at a low risk for development of t-MDS/AML (cumulative incidence: 0.4% and 0.9% at 5 years, respectively), patients treated on regimen C were at a 16-fold increased risk of developing t-MDS/AML (cumulative incidence: 11% at 5 years), when compared with those treated on regimen A. Increasing exposure to ifosfamide from 90 to 140 g/m2, cyclophosphamide from 9.6 to 17.6 g/m2, and doxorubicin from 375 to 450 mg/m2 increased the risk of t-MDS/AML significantly.This publication has 22 references indexed in Scilit:
- Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatmentBlood, 2003
- Acute Myeloid Leukemia and Myelodysplastic Syndrome After Doxorubicin-Cyclophosphamide Adjuvant Therapy for Operable Breast Cancer: The National Surgical Adjuvant Breast and Bowel Project ExperienceJournal of Clinical Oncology, 2003
- Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of BoneThe New England Journal of Medicine, 2003
- Risk of Leukemia after Platinum-Based Chemotherapy for Ovarian CancerThe New England Journal of Medicine, 1999
- Breast Cancer and Other Second Neoplasms after Childhood Hodgkin's DiseaseThe New England Journal of Medicine, 1996
- Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 1991
- High-dose ifosfamide with mesna uroprotection in Ewing's sarcomaCancer Chemotherapy and Pharmacology, 1989
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988
- A phase II study of ifosfamide in the treatment of recurrent sarcomas in young peopleCancer Chemotherapy and Pharmacology, 1986
- Ewing's SarcomaCA: A Cancer Journal for Clinicians, 1976